15/12/20209:29AM Dow Jones Mesoblast: No Reduction in Recurrent Non-Fatal Decompensated Heart Failure Events, Which Was Primary Endpoint (headline only)
With headline like this one, the shorts may exert pressure on the stock today for sure.....its a strong result but markets are fickle beasts and seeing "endpoint" usually meas tank time just like the Phase 2 NIH last November....funny times and shenanigans.
No 10 buck open for sure.
Just call it, just make the call.
Ann: Mesoblast Phase 3 Chronic Heart Failure Results, page-92
-
- There are more pages in this discussion • 931 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.03 |
Change
0.080(8.42%) |
Mkt cap ! $1.176B | |||
| Open | High | Low | Value | Volume |
| 95.5¢ | $1.03 | 95.0¢ | $43.38M | 42.28M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 72752 | $1.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.03 | 205100 | 2 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |